BOXED O
WARNING O
: O
WARNING O
: O
SERIOUS O
INFECTIONS O
AND O
MALIGNANCY O
WARNING O
: O
SERIOUS O
INFECTIONS O
AND O
MALIGNANCY O
EXCERPT O
: O
WARNING O
: O
SERIOUS O
INFECTIONS O
AND O
MALIGNANCY O
See O
full O
prescribing O
information O
for O
complete O
boxed O
warning O
. O

* O
Serious O
infections O
leading O
to O
hospitalization O
or O
death O
, O
including O
tuberculosis O
and O
bacterial O
, O
invasive O
fungal O
, O
viral O
, O
and O
other O
opportunistic O
infections O
, O
have O
occurred O
in O
patients O
receiving O
XELJANZ O
. O

( O
5.1 O
) O
* O
If O
a O
serious O
infection O
develops O
, O
interrupt O
XELJANZ O
until O
the O
infection O
is O
controlled O
. O

( O
5.1 O
) O
* O
Prior O
to O
starting O
XELJANZ O
, O
perform O
a O
test O
for O
latent O
tuberculosis O
; O
if O
it O
is O
positive O
, O
start O
treatment O
for O
tuberculosis O
prior O
to O
starting O
XELJANZ O
. O

( O
5.1 O
) O
* O
Monitor O
all O
patients O
for O
active O
tuberculosis O
during O
treatment O
, O
even O
if O
the O
initial O
latent O
tuberculosis O
test O
is O
negative O
. O

( O
5.1 O
) O
* O
Lymphoma O
and O
other O
malignancies O
have O
been O
observed O
in O
patients O
treated O
with O
XELJANZ O
. O

Epstein O
Barr O
Virus-associated O
post-transplant O
lymphoproliferative O
disorder O
has O
been O
observed O
at O
an O
increased O
rate O
in O
renal O
transplant O
patients O
treated O
with O
XELJANZ O
and O
concomitant O
immunosuppressive O
medications O
. O

( O
5.2 O
) O
SERIOUS O
INFECTIONS O
Patients O
treated O
with O
XELJANZ O
are O
at O
increased O
risk O
for O
developing O
serious O
infections B-OSE_Labeled_AE
that O
may O
lead O
to O
hospitalization O
or O
death B-NonOSE_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
and O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Most O
patients O
who O
developed O
these O
infections B-NonOSE_AE
were O
taking O
concomitant O
immunosuppressants B-NonOSE_AE
such O
as O
methotrexate O
or O
corticosteroids O
. O

If O
a O
serious O
infection B-NonOSE_AE
develops O
, O
interrupt O
XELJANZ O
until O
the O
infection B-NonOSE_AE
is O
controlled O
. O

Reported O
infections B-OSE_Labeled_AE
include O
: O
* O
Active B-OSE_Labeled_AE
tuberculosis I-OSE_Labeled_AE
, O
which O
may O
present O
with O
pulmonary B-OSE_Labeled_AE
or O
extrapulmonary O
disease I-OSE_Labeled_AE
. O

Patients O
should O
be O
tested O
for O
latent B-NonOSE_AE
tuberculosis I-NonOSE_AE
before O
XELJANZ O
use O
and O
during O
therapy O
. O

Treatment O
for O
latent B-Not_AE_Candidate
infection I-Not_AE_Candidate
should O
be O
initiated O
prior O
to O
XELJANZ O
use O
. O

* O
Invasive B-OSE_Labeled_AE
fungal I-OSE_Labeled_AE
infections I-OSE_Labeled_AE
, O
including O
cryptococcosis B-OSE_Labeled_AE
and O
pneumocystosis B-OSE_Labeled_AE
. O

Patients O
with O
invasive B-OSE_Labeled_AE
fungal I-OSE_Labeled_AE
infections I-OSE_Labeled_AE
may O
present O
with O
disseminated O
, O
rather O
than O
localized O
, O
disease O
. O

* O
Bacterial B-OSE_Labeled_AE
, O
viral O
, O
and O
other O
infections I-OSE_Labeled_AE
due O
to O
opportunistic I-OSE_Labeled_AE
pathogens O
. O

The O
risks O
and O
benefits O
of O
treatment O
with O
XELJANZ O
should O
be O
carefully O
considered O
prior O
to O
initiating O
therapy O
in O
patients O
with O
chronic O
or O
recurrent O
infection B-Not_AE_Candidate
. O

Patients O
should O
be O
closely O
monitored O
for O
the O
development O
of O
signs O
and O
symptoms O
of O
infection B-NonOSE_AE
during O
and O
after O
treatment O
with O
XELJANZ O
, O
including O
the O
possible O
development O
of O
tuberculosis B-NonOSE_AE
in O
patients O
who O
tested B-Not_AE_Candidate
negative I-Not_AE_Candidate
for I-Not_AE_Candidate
latent I-Not_AE_Candidate
tuberculosis I-Not_AE_Candidate
infection I-Not_AE_Candidate
prior O
to O
initiating O
therapy O
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

MALIGNANCIES O
Lymphoma B-OSE_Labeled_AE
and O
other O
malignancies B-OSE_Labeled_AE
have O
been O
observed O
in O
patients O
treated O
with O
XELJANZ O
. O

Epstein B-NonOSE_AE
Barr I-NonOSE_AE
Virus I-NonOSE_AE
- I-NonOSE_AE
associated I-NonOSE_AE
post I-NonOSE_AE
- I-NonOSE_AE
transplant I-NonOSE_AE
lymphoproliferative I-NonOSE_AE
disorder I-NonOSE_AE
has O
been O
observed O
at O
an O
increased O
rate O
in O
renal B-Not_AE_Candidate
transplant I-Not_AE_Candidate
patients O
treated O
with O
XELJANZ O
and O
concomitant O
immunosuppressive O
medications O
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
. O

